Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Dietary Supplement Health and Education Act provisions | Statement: [Title 21 of the United States Code, contains, Dietary Supplement Health and Education Act provisions]

Target entity: Dietary Supplement Health and Education Act provisions
Context triple: [Title 21 of the United States Code, contains, Dietary Supplement Health and Education Act provisions]

• A. Dietary Supplement Health and Education Act of 1994 chosen
  The Dietary Supplement Health and Education Act of 1994 is a U.S. law that defines and regulates dietary supplements as a category of food, setting labeling and safety standards while limiting the FDA’s pre-market approval authority.
• B. Federal Food, Drug, and Cosmetic Act
  The Federal Food, Drug, and Cosmetic Act is a key U.S. law that authorizes the Food and Drug Administration to regulate the safety, labeling, and marketing of food, drugs, medical devices, and cosmetics.
• C. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• D. Food and Drug Administration Modernization Act of 1997
  The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
• E. Food and Drug Administration Safety and Innovation Act of 2012
  The Food and Drug Administration Safety and Innovation Act of 2012 is a U.S. federal law that reauthorized and expanded FDA user fee programs while enhancing the agency’s authority over drug and medical device safety, innovation, and supply chain oversight.
• F. None of above.
• G. Unsure - the case is ambiguous/there is not enough information to decide.